X

Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) Stock Analysis

Small Cap
Evaluated by 1545 users | BSE: 532526 | NSE: DISHMAN |
Pharmaceuticals & Drugs
Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Return on Capital Employed 11.54%10.23%15.51%9.49%6%7.73%8.59%10.43%7.22%8.79%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 275359416353421463485473492510
Y-o-Y Gr. Rt.-30.5%15.8%-15.2%19.3%10.1%4.6%-2.3%4%3.7%
Adjusted EPS (Rs.) 3.763.696.334.262.423.174.135.33.285.22
Y-o-Y Gr. Rt.--1.9%71.5%-32.7%-43.2%31%30.3%28.3%-38.1%59.2%
Book Value per Share (Rs.) 18.4628.3234.0237.8439.6341.6344.8449.2851.7256.37
Adjusted Net Profit 54.258.910268.839.151.166.785.65384.2
Net Op. Cash Flow (Rs. Cr.) 21.242.590.811011825028.312614.5125
Debt to Cash Flow from Ops 14.16.183.23.964.761.9618.484.1843.445.04
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Dishman Pharmaceuticals & Chemicals Ltd. - (Amalgamated) should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 7.1%3.9%1.7%3.7%
Adjusted EPS 3.7%16.6%8.1%59.2%
Book Value per Share 13.27.37.99
Share Price 29.1% 14.7% - -
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Return on Equity (%) 24.6116.2820.2911.796.237.779.5311.246.489.64
Operating Profit Margin (%) 25.6925.6336.133.272433.3835.9637.2330.1233.46
Net Profit Margin (%) 19.716.3824.5719.519.2911.0313.7518.0810.7616.5
Debt to Equity 1.120.580.530.710.880.730.720.660.760.69
Working Capital Days 325307270347417436406467564638
Cash Conversion Cycle 183168133101796153508591
Entity Percentage Holding
Promoters 61.40%
Institutions 20.84%
Non-Institutions 17.76%
Pledged *35.7630.3117.2611.462.462.420.570.570.570.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Dishman Pharma(Amalg and arrived at the following conclusion:

Past 10 year's financial track record indicates that Dishman Pharma(Amalg is a average quality company. However, for specific investment actions please connect with your investment advisor.

The 5-year analysis of Dishman Pharma(Amalg's performance infers:

Dishman Pharma(Amalg earnings have grown by 16.6%, whereas share price has appreciated 14.7% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Dishman Pharma(Amalg share prices over the last 10 years. Here is what we found out:

Dishman Pharma(Amalg share price has appreciated 12.3% annually over the past ten years.

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year

Dishman Pharmaceuticals and Chemicals Limited (DPCL) was incorporated in 1983 as a research-oriented company. Later in 1989 the company started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds. The company became a global market leader and earned the status of the “Quat Company”. In the period of 10 years the production capacity was increased from 10MT per annum to 1500 Mt per annum.

In the year 1995, the company entered into a joint ventured with Schütz & Co, Germany and formed Schütz Dishman Biotech. This company manufactures Chlorhexidine Base, Chlorhexidine HCl, Chlorhexidine Acetate and Chlorhexidine Gluconate solution to cater European market. In 1995-96, the company expanded its activities for the development of many intermediates and APIs. In 1998 in order to penetrate in European and US market, the company formed two wholly-owned subsidiaries Dishman Europe and Dishman USA Inc. In 1998, the company forayed into contract research and manufacture sector. Within a period of 5 years DPCL was able to several contract research and manufacturing projects and later emerged as India’s leading CMO organization (Contract Manufacturing Outsourcing).

Headquartered at Ahmedabad, the company owns three manufacturing units, two located at Bavla and one at Naroda. Presently the company is manufactures a range of Bulk APIs, Intermediates, Specialties and Quats. The company has representative office located at Germany, Italy and Turkey.

DPCL is engaged in the manufacture of active pharmaceutical ingredients (APIs) intermediates. The Company operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quats and specialty chemicals. It provides a range of products to the global market, including a range of reagents, specialty chemicals, APIs and their intermediates.

Business units:

Dishman Specialty Chemicals, which manufactures Phase Transfer Catalysts;

Dishman Vitamins and Chemicals, which manufactures Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and laolin related products for pharmaceutical, cosmetic and related markets,

Dishman Disinfectants, which manufactures antiseptic and disinfectant formulations.

The products manufactured by the company include bulk drugs, phase transfer catalyst and fine chemicals

 

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback